GlassScriptPhysician profile
Jeffrey S Mandak
NPI 1386645232
$25,704.68
in general payments reported to CMS, 2019-2025
27 companies · $844 in 2025
The $844 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $363 · 2021: $421 · 2022: $503 · 2023: $15K · 2024: $8,208 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $9,975 · Food and Beverage: $2,807 · Travel and Lodging: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,750.10 |
| Consulting Fee | $9,975.00 |
| Food and Beverage | $2,806.74 |
| Travel and Lodging | $255.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $21,514.02 | 2019-2025 | Injectafer |
| Pfizer INC. | $715.15 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $584.72 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $370.66 | 2020-2025 | |
| Amgen INC. | $346.05 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $336.24 | 2019-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $305.95 | 2023-2025 | Onpattro, Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.03 | 2019-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $157.92 | 2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $154.53 | 2019-2022 | |
| Medtronic, INC. | $131.97 | 2023-2024 | Corevalve Evolut R, Cg Future |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $131.04 | 2019-2025 | Lifevest |
| Bridgebio Pharma, INC. | $119.56 | 2025 | Attruby |
| Novo Nordisk INC | $113.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| American Regent | $85.75 | 2023-2024 | Injectafer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $70.61 | 2022-2025 | Optimizer, Optimizer |
| Amarin Pharma, INC. | $63.88 | 2019-2021 | |
| Lantheus Medical Imaging, INC. | $47.74 | 2023-2024 | Definity |
| Bayer Healthcare Pharmaceuticals INC. | $41.11 | 2025 | |
| Baxter Healthcare | $35.58 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Cardiac Ambulatory Monitor |
| Actelion Pharmaceuticals US, INC. | $23.79 | 2025 | Opsynvi |
| Kestra Medical Technology Services, INC. | $23.79 | 2024 | Assure Wcd |
| Scpharmaceuticals INC. | $22.85 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $17.96 | 2024 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $15.85 | 2020 | |
| Esperion Therapeutics, INC. | $15.23 | 2025 | Nexletol |
| Bardy Diagnostics, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mandak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.